Drug Trial Radar · NCT06587035
A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jan 30, 2025
Primary completion
Sep 5, 2028
Study completion Sep 5, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety of Somatrogon for the treatment of pediatric growth hormone deficiency (p GHD) in India. Pediatric GHD is a condition caused by too less amounts of growth hormone in the body. Children with GHD have a short height. GHD can be present at birth or develop later. The condition occurs if the pituitary gland makes too little growth hormone. This is a small gland at the bottom of the brain that releases hormones that affect growth and other body functions. This study is seeking for participants who are: * confirmed with p GHD. * given Somatrogon to be taken as an injection. The safety of Somatrogon injection will be checked based on side effects. These side effects can happen within 3 years after taking Somatrogon. A side effect is something (expected or unexpected) that you feel was caused by a medicine or treatment you take. The study doctor will collect side effect information and put the information on patient's case form. Follow-up of the patient's will be performed via clinic re-visit or over a call. It is not a rule for the participants to visit the clinic in this study. This study will help to see if Somatrogon is safe.
Conditions
- Dwarfism, Pituitary
Interventions
SomatrogonDrug
Long-acting growth hormone for pediatric growth hormone deficiency.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events in participants on SomatrogonTime frame: 3 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Shivajoyti Clinic
Bengaluru, Karnataka, India · Recruiting
Apollo Children's Hospital
Chennai, Tamil Nadu, India · Recruiting
G Kuppuswamy Naidu Memorial Hospital
Coimbatore, Tamil Nadu, India · Recruiting
Apollo Speciality Hospital
Madurai, Tamil Nadu, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.